Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 4.8% – Time to Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was down 4.8% during trading on Tuesday . The stock traded as low as $15.06 and last traded at $14.76. Approximately 63,820 shares changed hands during trading, a decline of 95% from the average daily volume of 1,262,963 shares. The stock had previously closed at $15.50.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Citigroup cut their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. B. Riley restated a “buy” rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Price Performance

The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The firm has a market cap of $2.03 billion, a P/E ratio of -2.87 and a beta of 0.92. The company has a fifty day moving average price of $18.51 and a two-hundred day moving average price of $19.81.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). Equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, COO Patrick O’brien sold 29,184 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $578,426.88. Following the transaction, the chief operating officer now directly owns 535,201 shares of the company’s stock, valued at $10,607,683.82. This represents a 5.17 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the transaction, the insider now directly owns 272,122 shares in the company, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 289,167 shares of company stock worth $5,106,735. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ARWR. Avoro Capital Advisors LLC raised its position in shares of Arrowhead Pharmaceuticals by 25.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company’s stock valued at $208,889,000 after buying an additional 2,222,223 shares in the last quarter. State Street Corp increased its holdings in Arrowhead Pharmaceuticals by 8.8% in the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after purchasing an additional 516,569 shares in the last quarter. Slate Path Capital LP boosted its position in Arrowhead Pharmaceuticals by 7.1% during the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company’s stock worth $98,362,000 after buying an additional 347,000 shares during the period. Geode Capital Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock valued at $57,426,000 after acquiring an additional 26,171 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $38,622,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.